http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#Head http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#assertion http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#provenance http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#pubinfo http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#assertion http://purl.obolibrary.org/obo/DOID_8552 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8552 http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08901 http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association http://www.w3.org/2000/01/rdf-schema#label iclusig ponatinib is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315i positive cml chronic phase accelerated phase or blast phase or t315i positive philadelphia chromosome positive acute lymphoblastic leukemia ph all iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase accelerated phase or blast phase chronic myeloid leukemia cml or ph all for whom no other tyrosine kinase inhibitor tki therapy is indicated treatment of adult patients with t315i positive cml chronic phase accelerated phase or blast phase or t315i positive philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml 5 7 limitations of use iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase cml see warnings and precautions 5 7 http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08901 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#provenance http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#pubinfo http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig http://purl.org/nanopub/x/hasSignature gbjZSswwLDxFeq8RkbUz7+V/FmsEPK6IcPPDcHfqYV5DtsO6O8lnIvBBX/wgd32VByPr92bBWEmyPLJjdCzvrmMSN9cExKDd/MfD0MVR22eAf6woFzwZ0hQE2SN8QlaDFmL0+/CRBpNuNHweQt5kIaF9u2nW4O5/VbRJktU/ro0= http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY http://purl.org/dc/terms/created 2021-07-03T14:30:54.514+02:00 http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAhnDhUC1mAbRyVa7R9UMT92CEzEYzvjOkV1kMkVkLwoY https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs